Mathew J. Garnett
Wellcome Trust Sanger Institute
164 Papers
384 Citations
Mathew J. Garnett is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 42, co-authored 142 publications. Previous affiliations of Mathew J. Garnett include Institute of Cancer Research & University of British Columbia.
Chat about Author
Papers
Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
Federica Eduati,Patricia Jaaks,Jessica Wappler,Thorsten Cramer,Christoph A. Merten,Mathew J. Garnett,Julio Saez-Rodriguez +6 more
TL;DR: Researchers develop patient-specific logic models from cancer biopsy screenings to prioritize personalized combination therapies, correcting a minor error in a previously published figure that does not impact the paper's conclusions or interpretations.
Metabolic Activation of Benzo[a]pyrene by Human Tissue Organoid Cultures
Angela L Caipa Garcia,Jill E. Kucab,Halh Al-Serori,Rebekah S. S. Beck,Franziska Fischer,Matthias Hufnagel,Andrea Hartwig,Andrew Floeder,Silvia Balbo,Hayley E. Francies,Mathew J. Garnett,Meritxell Huch,Jarno Drost,Matthias Zilbauer,Volker M. Arlt,David Phillips +15 more
TL;DR: In this paper , the ability of human organoids derived from normal gastric, pancreas, liver, colon and kidney tissues to metabolise the environmental carcinogen benzo[a]pyrene (BaP) was investigated.
Cancer research needs a better map.
Jesse S. Boehm,Mathew J. Garnett,David J. Adams,Hayley E. Francies,Todd R. Golub,William C. Hahn,Francesco Iorio,James M. McFarland,Leopold Parts,Francisca Vazquez +9 more
TL;DR: It is time to move beyond tumour sequencing data to identify vulnerabilities in cancers as discussed by the authors, and this is the direction we should take in this paper. But it is difficult to do so.
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
Emanuel Gonçalves,Aldo Segura-Cabrera,Clare Pacini,Gabriele Picco,Fiona M. Behan,Patricia Jaaks,Elizabeth A. Coker,Donny van der Meer,Andrew Barthorpe,Howard Lightfoot,Tatiana Mironenko,Alexandra Beck,Laura Richardson,Wanjuan Yang,Ermira Lleshi,James Hall,Charlotte Tolley,Caitlin Hall,Iman Mali,Frances Thomas,James Morris,Andrew R. Leach,James T. Lynch,Ben Sidders,Claire Crafter,Francesco Iorio,Stephen Fawell,Mathew J. Garnett +27 more
TL;DR: Linking drug and gene dependency together with genomic data sets uncovered contexts in which molecular networks when perturbed mediate cancer cell loss‐of‐fitness and thereby provide independent and orthogonal evidence of biomarkers for drug development.
Abstract A44: A landscape of pharmacogenomic interactions in cancer
Francesco Iorio,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +8 more
TL;DR: It is found that cell-lines faithfully recapitulate oncogenic aberrations identified in tumors, and that many of these associate with drug sensitivity or resistance.